COVID-19 Induced Immunosuppression resulting in Pulmonary Mucormycosis : A Long COVID sequalae

Authors

  • Dhruv Talwar Post Graduate Resident, Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Science, Sawangi meghe, Wardha, Maharashtra, India
  • Sunil Kumar Professor, Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Science, Sawangi meghe, Wardha, Maharashtra, India
  • Sourya Acharya Professor and Head of Department, Department of Medicine,Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Science, Sawangi meghe, Wardha, Maharashtra, India
  • Sparsh Madaan Post Graduate Resident, Department of Obstetrics and Gynaecology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Science, Sawangi meghe, Wardha, Maharashtra,India 442001
  • Vidyashree Hulkoti Post Graduate Resident, Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Science, Sawangi meghe, Wardha, Maharashtra, India

DOI:

https://doi.org/10.3329/jom.v22i2.56707

Keywords:

Pulmonary Mucormycosis, Long Covid, Immunosuppression

Abstract

With increasing incidence of Severe Acute Respiratory Distress Virus 2(SARS -CoV -2) in India, there has been growing reports of super infections in post covid 19 period. Long COVID refers to persistence of COVID19 symptoms for weeks to months. While most common manifestation of long COVID is fatigue and ill health, it may lead to development of life-threatening complications like Pulmonary Mucormycosis. We report a case of 54 year young, non-diabetic previously healthy male who had moderate COVID19 treated with low dose steroids and recovered completely, only to present with hemoptysis 3 months later on High Resolution Computed Tomography Scan of the Chest and Rhizopus fungi on bronchoalveolar lavage confirming Post Covid Pulmonary Mucormycosis in non-immunocompromised host. Patient was managed with dual antifungal therapy intravenous Liposomal Amphotericin B and Posaconazole for 3 weeks, followed by oral Posaconazole.

J MEDICINE 2021; 22: 150-154

Downloads

Download data is not yet available.
Abstract
1
PDF
2

Downloads

Published

2021-12-01

How to Cite

Talwar, D. ., Kumar, S. ., Acharya, S. ., Madaan, S. ., & Hulkoti, V. . (2021). COVID-19 Induced Immunosuppression resulting in Pulmonary Mucormycosis : A Long COVID sequalae. Journal of Medicine, 22(2), 150–154. https://doi.org/10.3329/jom.v22i2.56707

Issue

Vol. 22 No. 2 (2021)

Section

Case Reports

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).